References
- Aoky Y, Watanabe M, Sasaki M, et al (2001). Prognostic factors and failure pattern in lymph node- negative stage IB and II cervical carcinoma treated with radical hysterectomy and postoperative irradiation. Gynecol Obstet Invest, 52, 13-7. https://doi.org/10.1159/000052933
- Bosch FX, Manos MM, Munoz N, et al (1995). International Biological Study on Cervical Cancer (IBSCC) Study Group. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst, 87, 796-802. https://doi.org/10.1093/jnci/87.11.796
- Brinton LA, Tashima KT, Lehman HF, et al (1987). Epidemiology of cervical cancer by cell type. Cancer Res, 47, 1706-11
- Cho NM, Kim YB, Park TK, e al (2003). p63 and EGFR as prognostic predictors in stage IIB radiation-treated cervical squamous cell carcinoma. Gynecol Oncol, 91, 346-53. https://doi.org/10.1016/S0090-8258(03)00504-3
- Ferlay J, Shin HR, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008, Int J Cancer, 127, 2893-917 https://doi.org/10.1002/ijc.25516
- FIGO Committee on Gynecologic Oncology (2000). Staging classifications and clinical practice guidelines of gynecologic cancers. Int J Gynecol Obstet, 70, 207-312. https://doi.org/10.1016/S0020-7292(00)00300-3
- Graflund M, Sorbe B, Bryne M, Karlsson M (2002). The prognostic value of a histologic grading system, DNA profile and MIB-1 expression in early stages of cervical squamous cell carcinoma. Int J Gynecol Cancer, 12, 149-57. https://doi.org/10.1046/j.1525-1438.2002.01088.x
- Jain D, Srinivasan R, Patel F, Gupta SK (2003). Evaluation of p53 and Bcl-2 expression as prognostic markers in invasive cervical carcinoma stage IIb/III patients treated by radiotherapy. Gynecol Oncol, 88, 22-8. https://doi.org/10.1006/gyno.2002.6838
-
Khalifa YB, Teissier S, Tan MK, et al (2011). The Human Papillomavirus E6 Oncogene Represses a Cell Adhesion Pathway and Disrupts Focal Adhesion through Degradation of Tap63
$\beta$ upon Transformation. Plos Pathogens, 7, 1-9. - Khunamornpong S, Siriaunkgul S, Manusirivithaya S, et al (2006). Prognostic value of p53 expression in early stage cervical carcinoma treated by surgery. Asian Pac J Cancer Prev, 9, 48-52.
- Koh WJ, Panwala K, Greer B (2000). Adjuvant therapy for high risk, early stage cervical cancer. Semin Radiat Oncol, 10, 51-60. https://doi.org/10.1016/S1053-4296(00)80021-1
- Lu X (2004). p53, HPV and Cervical Cancer. Postgraduate Training Course in Reproductive health Geneva.
- Munger K (2002). The role of human papillomaviruses in human cancers. Front Biosci, 7, 641-9. https://doi.org/10.2741/munger
- Nygard JF, Skare GB, Thoresen SO (2002). The cervical cancer screening program in Norway,1992-2000: Changes in pap smear coverage and incidence of cervical cancer. J Med Screen, 9, 86-91. https://doi.org/10.1136/jms.9.2.86
- Quade BJ, Yang A, Wang Y, et al (2001). Expression of the p53 homologue p63 in early cervical neoplasia. Gynecol Oncol, 80, 24-9. https://doi.org/10.1006/gyno.2000.5953
- Shiohara S, Shiozawa T, Miyamoto T, et al (2005). Expression of cyclins, p53, and ki-67 in cervical squamous cell carcinomas: overexpression of cyclin A is a poor prognostic factor in stage Ib and II disease. Virchows Arch, 446, 626-33. https://doi.org/10.1007/s00428-005-1252-0
- Shirendeb U, Hishikawa Y, Moriyama S, et al (2009). Huma Papillomavirus infection and its possible correlation with p63 expression in cervical cancer in Japan, Mongolia, and Myanmar. Acta Histochem. Cytochem, 42, 181-90
- Tavassoli FA, Devilee P (2003 )(eds.)World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon: IARC Press .
- Tiltman AJ (2005). The pathology of cervical tumours. Best Pract Res Clin Obstet Gynaecol, 19, 485-500, https://doi.org/10.1016/j.bpobgyn.2005.02.003
- Tsujita-Kyutoku M, Kiuchi K, Danbara N, et al (2003). p63 expression in normal human epidermis and epidermal appendages and their tumors. J Cutan Pathol, 30, 11-7. https://doi.org/10.1034/j.1600-0560.2003.300102.x
- Vasilescu F, Ceasu M, Tanase C, Stanculescu, et al (2009). p53, p63, Ki-67 assessment in HPV-induced cervical neoplasia. Rom J Morphol Embryol, 50, 357-61.
- Viczaino AP, Moreno V, Bosch FX, et al (2000). International trends in incidence of cervical cancer. II. Squamous-cell carcinoma. Int J Cancer, 86, 429-35 https://doi.org/10.1002/(SICI)1097-0215(20000501)86:3<429::AID-IJC20>3.0.CO;2-D
- Vosmik M, Laco J, Sirak I, Baranek M, et al (2013). Prognostic significance of HPV status and expression of selected markers (HER2/neu, EGFR, VEGF, CD34, p63, p53 and Ki-67) on outcome after (chemo) radiotherapy in patients with squamous cell carcinoma of uterine cervix. Pathol Oncol Res. [Epub ahead of print]
- Wang TY, Chen BF, Yang YC, et al (2001). Histologic and immunophenotypic classification of cervical carcinomas by expression of the p53 homologue p63: a study of 250 cases. Hum Pathol, 32, 479-86. https://doi.org/10.1053/hupa.2001.24324
- Zur Hausen (2002). Papillomavirusses and cancer: from basic studies to clinical application. Nat Rev Cancer, 2, 342-350. https://doi.org/10.1038/nrc798
Cited by
- Biomarkers of HIV-associated Cancer vol.6, pp.1179-299X, 2014, https://doi.org/10.4137/BIC.S15056
- Survival Rates of Cervical Cancer Patients in Malaysia vol.16, pp.7, 2015, https://doi.org/10.7314/APJCP.2015.16.7.3067